证券时报·2026-01-06 15:21Group 1 - The core viewpoint of the article is the announcement of the termination of control right change plans by Baohua Pharmaceutical and Siwei Liekong, indicating stability in their operations and financial conditions [3][6][10]. Group 2 - Baohua Pharmaceutical's stock was suspended on December 29, 2025, due to potential control right changes, with a recent market capitalization of 4.707 billion [4][13]. - Prior to suspension, Baohua Pharmaceutical's stock price increased by 6.54% and 5.88% in the two trading days leading up to the announcement [4][13]. - For the first three quarters of 2025, Baohua Pharmaceutical reported revenue of 299 million, a year-on-year increase of 2.74%, and a net profit of 32.67 million, up 36.41% year-on-year [6]. Group 3 - Siwei Liekong's stock was also suspended on December 29, 2025, with a total market capitalization of 10.6 billion [7][9]. - The company stated that the termination of the control right change plan would not have a significant adverse impact on its operational performance and financial status [10].